中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Viral Hepatitis
NASH
HIV/AIDS
Pipeline & Products
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
Investors
Financials & Filing
Presentation Materials
Next Day Disclosure Returns - Share Buyback
2020-10-19
Next Day Disclosure Returns - Share Buyback
2020-10-16
Next Day Disclosure Returns - Share Buyback
2020-10-15
Next Day Disclosure Returns - Share Buyback
2020-10-14
Next Day Disclosure Returns - Share Buyback
2020-10-12
Voluntary Announcement - Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42, an FXR Agonist
2020-10-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020
2020-09-30
2020 Interim Report
2020-09-24
Voluntary Announcement - Gannex Filed IND in the U.S. for Its NASH Drug Candidate ASC42, an FXR Agonist
2020-09-14
Voluntary Announcement - Gannex and Galmed Expand Development Programs for NASH through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
2020-09-09
«
2
3
4
5
»